Why Partner

As the only event exclusively dedicated to glioblastoma drug development, the conference provided an unparalleled opportunity for industry leaders to engage with top experts from every corner of the GBM space. Attendees included influential figures from large pharma, biotech, neuro‑oncology, clinical practice, investment, and academia, all aligned in their commitment to advancing progress in glioblastoma treatment. With the rising need for innovative models, diagnostics, and delivery technologies, the summit became an ideal platform to identify market gaps and uncover opportunities for new products and services to shape future solutions.

Building on recent breakthroughs, such as Kite Pharma’s encouraging survival data and advancements in dual‑target CAR T‑cell therapies demonstrating slowed tumor progression, the GBM research community arrived with a renewed sense of optimism. As the field approached a critical inflection point, momentum gathered around redefining how glioblastoma and other CNS tumors could be treated in the years ahead.

The event offered companies a unique opportunity to position themselves at the forefront of these developments, aligning with cutting‑edge neuro‑oncology research and therapeutic innovation. It became the perfect moment for organizations to establish valuable partnerships, elevate their visibility, and demonstrate their role in advancing transformative solutions for one of the most challenging areas of oncology.

Together, participants contributed to a movement actively shaping the future of GBM treatment, driving collaboration, accelerating innovation, and bringing new hope to patients and families impacted by this devastating disease.